How long does it take to see obvious results after taking Alpelisib?

Alpelisib（Alpelisib)-Piqray is a selective PI3Kα inhibitor, mainly used in patients with hormone receptor-positive, HER2-negative breast cancer related to PIK3CA mutations. Many patients are concerned about a practical question before starting to take the drug: how long will it take to see a more obvious therapeutic effect after taking Apelvis. Judging from overseas clinical experience, the onset rhythm of this type of targeted drugs is different from that of traditional chemotherapy, and more emphasis is placed on the cumulative effect of continuous inhibition of tumor signaling pathways.

Generally speaking, Apelvis is not an "immediately effective" drug. Its mechanism of action is to gradually reduce the proliferation and survival ability of tumor cells by inhibiting the PI3K-AKT-mTOR pathway. In some patients, signs of disease stabilization may be observed in imaging or tumor-related indicators during early follow-up after treatment, but to be truly considered to have a "clear effect" often requires a continuous and standardized treatment process and a comprehensive judgment based on multiple evaluation results.

Overseas data generally emphasize that the key to judging whether Apelvis is effective is not whether the tumor shrinks significantly in the short term, but whether the disease is continuously controlled, including stable lesions, improvement of symptoms, or slowdown of progression. Therefore, in the early stage of treatment, if there is no obvious deterioration, there is usually no rush to deny the efficacy, but continue to observe its long-term effect trend.

In terms of the duration of medication, the treatment principle of Apelvis is relatively clear, and it is usually continued until the disease progresses or unacceptable toxic reactions occur. This means that as long as patients continue to benefit from treatment and adverse effects are manageable, treatment has continued value. It should be noted that some common adverse reactions may be more prominent in the early stages, but with supportive treatment and dose adjustment, the tolerance of some patients will gradually improve.

Reference materials:https://www.piqray.com/